HC Wainwright Reaffirms “Buy” Rating for Replimune Group (NASDAQ:REPL)

Replimune Group (NASDAQ:REPL)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $17.00 price target on the stock. HC Wainwright’s price target points to a potential upside of 45.42% from the company’s current price.

Other analysts have also recently issued research reports about the company. JPMorgan Chase & Co. increased their target price on Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, September 24th. Roth Mkm began coverage on shares of Replimune Group in a research report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price objective for the company. Finally, Roth Capital raised shares of Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $16.80.

Replimune Group Price Performance

NASDAQ:REPL opened at $11.69 on Tuesday. The company has a quick ratio of 13.46, a current ratio of 13.46 and a debt-to-equity ratio of 0.16. The firm has a market cap of $798.66 million, a PE ratio of -3.83 and a beta of 1.19. Replimune Group has a 12 month low of $4.92 and a 12 month high of $12.97. The company’s 50-day moving average price is $11.44 and its two-hundred day moving average price is $9.50.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.07. On average, equities analysts anticipate that Replimune Group will post -3.05 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Emily Luisa Hill sold 8,938 shares of Replimune Group stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $10.18, for a total transaction of $90,988.84. Following the completion of the sale, the chief financial officer now owns 101,057 shares in the company, valued at $1,028,760.26. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 8.80% of the company’s stock.

Institutional Trading of Replimune Group

Institutional investors have recently bought and sold shares of the business. Millennium Management LLC boosted its position in shares of Replimune Group by 575.1% in the 2nd quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock worth $28,062,000 after purchasing an additional 2,656,173 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Replimune Group by 12.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock valued at $53,505,000 after purchasing an additional 699,679 shares during the period. Jacobs Levy Equity Management Inc. acquired a new stake in Replimune Group in the first quarter worth $1,088,000. Acadian Asset Management LLC bought a new position in shares of Replimune Group during the first quarter worth $927,000. Finally, Cubist Systematic Strategies LLC grew its holdings in shares of Replimune Group by 282.2% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 72,207 shares of the company’s stock valued at $650,000 after buying an additional 53,313 shares during the period. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.